Compare Cipla with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DIVIS LABORATORIES - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DIVIS LABORATORIES CIPLA/
DIVIS LABORATORIES
 
P/E (TTM) x 23.3 34.6 67.3% View Chart
P/BV x 2.4 6.6 35.8% View Chart
Dividend Yield % 0.7 0.9 73.5%  

Financials

 CIPLA   DIVIS LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-19
DIVIS LABORATORIES
Mar-19
CIPLA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6781,639 41.4%   
Low Rs4841,115 43.4%   
Sales per share (Unadj.) Rs198.2186.3 106.4%  
Earnings per share (Unadj.) Rs18.551.0 36.4%  
Cash flow per share (Unadj.) Rs35.057.3 61.0%  
Dividends per share (Unadj.) Rs3.0016.00 18.8%  
Dividend yield (eoy) %0.51.2 44.5%  
Book value per share (Unadj.) Rs186.3261.8 71.2%  
Shares outstanding (eoy) m805.70265.47 303.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.97.4 39.6%   
Avg P/E ratio x31.427.0 116.0%  
P/CF ratio (eoy) x16.624.0 69.1%  
Price / Book Value ratio x3.15.3 59.3%  
Dividend payout %16.231.4 51.6%   
Avg Mkt Cap Rs m468,031365,592 128.0%   
No. of employees `00022.611.8 191.1%   
Total wages/salary Rs m28,5655,423 526.8%   
Avg. sales/employee Rs Th7,053.14,175.1 168.9%   
Avg. wages/employee Rs Th1,261.5457.7 275.6%   
Avg. net profit/employee Rs Th659.11,141.8 57.7%   
INCOME DATA
Net Sales Rs m159,71049,463 322.9%  
Other income Rs m4,7661,556 306.2%   
Total revenues Rs m164,47551,019 322.4%   
Gross profit Rs m30,97318,718 165.5%  
Depreciation Rs m13,2631,689 785.3%   
Interest Rs m1,68435 4,812.3%   
Profit before tax Rs m20,79118,551 112.1%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6955,023 113.4%   
Profit after tax Rs m14,92413,527 110.3%  
Gross profit margin %19.437.8 51.2%  
Effective tax rate %27.427.1 101.2%   
Net profit margin %9.327.3 34.2%  
BALANCE SHEET DATA
Current assets Rs m124,26646,501 267.2%   
Current liabilities Rs m37,7158,468 445.4%   
Net working cap to sales %54.276.9 70.5%  
Current ratio x3.35.5 60.0%  
Inventory Days Days91131 69.3%  
Debtors Days Days9586 110.5%  
Net fixed assets Rs m105,19025,797 407.8%   
Share capital Rs m1,611531 303.5%   
"Free" reserves Rs m148,51168,962 215.4%   
Net worth Rs m150,12369,493 216.0%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63380,383 298.1%  
Interest coverage x13.3531.0 2.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.6 108.3%   
Return on assets %6.916.9 41.1%  
Return on equity %9.919.5 51.1%  
Return on capital %11.826.7 44.3%  
Exports to sales %34.70-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m57,41041,238 139.2%   
Fx outflow Rs m19,04112,405 153.5%   
Net fx Rs m38,36828,833 133.1%   
CASH FLOW
From Operations Rs m16,9119,543 177.2%  
From Investments Rs m-16,687-6,854 243.5%  
From Financial Activity Rs m-3,487-2,459 141.8%  
Net Cashflow Rs m-3,451230 -1,503.1%  

Share Holding

Indian Promoters % 16.0 52.0 30.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.8 103.4%  
FIIs % 23.7 19.0 124.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.2 152.3%  
Shareholders   161,166 31,796 506.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 18, 2019 (Close)

TRACK CIPLA

CIPLA - ORCHID PHARMA LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS